| Non-Small Cell Lung Carcinoma
Hyrnuo vs Libtayo
Side-by-side clinical, coverage, and cost comparison for non-small cell lung carcinoma.Deep comparison between: Hyrnuo vs Libtayo with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsLibtayo has a higher rate of injection site reactions vs Hyrnuo based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Libtayo but not Hyrnuo, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Hyrnuo
Libtayo
At A Glance
Oral
Twice daily
HER2 kinase inhibitor
IV infusion
Every 3 weeks
PD-1 inhibitor
Indications
- Non-Small Cell Lung Carcinoma
- Squamous cell carcinoma of skin
- Basal cell carcinoma
- Non-Small Cell Lung Carcinoma
Dosing
Non-Small Cell Lung Carcinoma 20 mg orally twice daily with food until disease progression or unacceptable toxicity.
Squamous cell carcinoma of skin (metastatic/locally advanced) 350 mg IV infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.
Squamous cell carcinoma of skin (adjuvant) 350 mg IV infusion every 3 weeks for 12 weeks followed by 700 mg every 6 weeks, or 350 mg every 3 weeks, until disease recurrence, unacceptable toxicity, or up to 48 weeks.
Basal cell carcinoma 350 mg IV infusion over 30 minutes every 3 weeks until disease progression, unacceptable toxicity, or up to 24 months.
Non-Small Cell Lung Carcinoma 350 mg IV infusion every 3 weeks as single agent or in combination with platinum-based chemotherapy until disease progression or unacceptable toxicity.
Contraindications
—
—
Adverse Reactions
Most common (>20%) Diarrhea, rash, paronychia, stomatitis, nausea
Serious Diarrhea, pneumonia, dyspnea, pleural effusion
Most common (>=15%) Fatigue, musculoskeletal pain, rash, diarrhea, anemia.
Serious Immune-mediated adverse reactions (pneumonitis, colitis, hepatitis, endocrinopathies, nephritis, exfoliative dermatologic conditions, myocarditis, neurological toxicities), infusion-related reactions, allogeneic HSCT complications, pneumonia.
Pharmacology
Sevabertinib is a reversible kinase inhibitor of HER2 (ERBB2) that also exhibits activity against EGFR; it inhibits HER2 phosphorylation and downstream signaling in cancer cells harboring HER2 alterations and demonstrates antitumor activity in NSCLC models with activating HER2 exon 20 mutations.
Cemiplimab-rwlc is a recombinant human IgG4 monoclonal antibody (PD-1 inhibitor) that binds to PD-1 and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Hyrnuo
- Covered on 5 commercial plans
- PA (12/12) · Step Therapy (0/12) · Qty limit (11/12)
Libtayo
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (0/12)
UnitedHealthcare
Hyrnuo
- Covered on 4 commercial plans
- PA (1/8) · Step Therapy (0/8) · Qty limit (1/8)
Libtayo
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Hyrnuo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (3/3)
Libtayo
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Hyrnuo.
Cost estimate not availableAssistance Fund: Non-Small Cell Lung Cancer (NSCLC)
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
HyrnuoView full Hyrnuo profile
LibtayoView full Libtayo profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.